WASHINGTON — The White House has withdrawn the nomination of Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration, pulling her name on Tuesday evening just hours before a key Senate committee was set to vote on her confirmation.
Overton, a medical doctor who serves as deputy director for the White House Domestic Policy Council, was nominated by President Donald Trump in August to lead the agency. Her nomination met resistance on Capitol Hill from both Democrats and Republicans over her record on tobacco policy, abortion medication, and public health guidelines, according to news reports.
The Senate Health, Education, Labor and Pensions Committee was set to vote on her nomination Wednesday. Axios first reported the administration’s decision to withdraw her nomination, which was later confirmed by a senior administration official and reported by outlets including CBS News and Fox News.
Pushback and Confirmation Hurdles
Overton struggled to build sufficient support among Senate lawmakers leading up to the scheduled panel vote, CBS News reported. Detractors raised questions regarding her managerial experience, her past commentary on the abortion drug mifepristone, and her support for the administration’s e-cigarette and vaping policies, according to the New York Post.
During her September confirmation hearing, Overton faced questioning from lawmakers on multiple fronts. Sen. Bernie Sanders, I-Vt., pressed her on healthcare access, while Sen. Maggie Hassan, D-N.H., and Sen. Ed Markey, D-Mass., questioned her about comments made by Trump regarding childhood vaccine schedules. Overton affirmed during the hearing that the combined measles, mumps, and rubella (MMR) vaccine is safe and effective, describing it as a crucial tool during disease outbreaks, Fox News reported.
External advocacy groups also targeted her nomination. SBA Pro-Life America pressed the administration to secure explicit policy commitments regarding mail-order abortion drugs before advancing any nominee. Meanwhile, anti-vaping activists circulated flyers across Capitol Hill opposing her nomination due to her stance on e-cigarettes, the New York Post reported.
Disagreement Over Confirmation Path
Senate HELP Committee Chairman Bill Cassidy, R-La., offered a different assessment of the situation late Tuesday, contending that Overton had enough support to clear the committee and pass the full Senate.
“I believe she would have had the votes to pass out of committee and pass the full Senate,” Cassidy said in a statement, arguing that the White House “abandoned a viable confirmation path.”
Cassidy indicated that pro-life senators were seeking final assurances from the Trump administration on life issues, but the White House chose to withdraw the nomination instead, CBS News reported. Cassidy had previously expressed concerns on social media about Overton’s involvement in efforts to alter childhood vaccine guidelines, calling that aspect of her record “almost disqualifying.”
The FDA, which oversees regulatory decisions impacting roughly 20 percent of U.S. consumer spending, has been without a Senate-confirmed leader since May, when Dr. Marty Makary resigned from the post. The regulatory body is currently headed by acting Commissioner Kyle Diamantas.
What Comes Next for FDA Leadership
A senior administration official told Axios that the White House intends to seek a new leadership approach at the agency that aligns with its broader health agenda. Administration officials have already begun discussing other potential candidates for the top FDA role, including options to install an acting chief who would not require Senate confirmation, CBS News reported.
Among those under consideration is Sen. Roger Marshall, R-Kan., an obstetrician who lost his reelection campaign earlier this month, according to reporting by CBS News and the New York Post. With limited time remaining before a new Congress convenes in January, any future Senate-confirmed commissioner faces a narrow window for confirmation under the current chamber leadership.



